This profile was last updated on //
Is this you? Claim your profile.
600 Technology Park Suite 200
Insulet Corporation is a medical device company that develops, manufactures and markets insulin infusion system for people with insulin-dependent diabetes. The Company’s OmniPod Insulin Management System (OmniPod System) consists of its OmniPod disposable
Find other employees at this company (587)
(196 Total References)
BEDFORD, Mass., Sept. 26 ...
BEDFORD, Mass., Sept. 26 /PRNewswire-FirstCall/ -- Insulet Corporation (Nasdaq: PODD), the manufacturer and marketer of the OmniPod® Insulin Management System, today announced that Duane DeSisto, Chief Executive Officer, will participate in the William Blair Small Cap Growth Conference.
Mr. DeSisto is sc...
BEDFORD, Mass., Aug. 29 /PRNewswire-FirstCall/ -- Insulet Corporation (Nasdaq: PODD), the manufacturer and marketer of the OmniPod® Insulin Management System, today announced that Duane DeSisto, Chief Executive Officer, will participate in the Thomas Weisel Partners Healthcare Conference.
Insulet Appoints Timothy J. Scannell to Board of Directors (NASDAQ:PODD)
Duane DeSisto, Insulet ...
Duane DeSisto, Insulet Corporation's President and Chief Executive Officer, stated, "The Board believes that a Shareholders Rights Plan enhances its ability to protect shareh...
BUSINESS ADVISOR: MGI's business advisor is Duane DeSisto, who has been involved in multiple successful medical device startup companies.
He was the CFO of Zoll Medical Corporation where he managed the company's manufacturing and service functions and the company's successful IPO in 1992.
He was the CEO of Insulet Corporation where he led the development of the OmniPod, the world's first tubing free, disposable insulin pump.
He assembled the management team, raised over $350 million in working capital, obtained multiple FDA approvals, established international partnerships, grew the company to 300+ employees and expanded revenues to $100 million in 2010.
When funded, MGI will be run by a full-time COO.
Mr. Desisto will sit on the board of MGI and either play a direct role in its management or in assembling the full time management team.
"2013 was one of the most ...
"2013 was one of the most exciting years in Insulet ' s history, and I am proud of all that our team accomplished, " said Duane DeSisto, President and Chief Executive Officer of Insulet. The market for Insulet ' s securities was open, well-developed and efficient at all relevant times.Record owners and other members of the Class may be identified from records maintained by Insulet or its transfer agent and may be notified of the pendency of this action by mail, using the form of notice similar to that customarily used in securities class actions.
Insulet (NSDQ:PODD) said today that it inked a deal with Mode Automated Glucose Control to develop an artificial pancreas using its flagship OmniPod device. Revenue increased by 35% within the OmniPod business and 20% overall," said Duane DeSisto, President and Chief Executive Officer of Insulet.We are confident that we have the right strategy and team to take Insulet to the next level and ensure OmniPod remains well-positioned for continued adoption in the U.S. and international markets
16.Defendant Duane DeSisto ( "DeSisto") was Chief Executive Officer ( "CEO") and a director of Insulet until September 16, 2014.